Cholesterol, HDL ; Cholesterol ; Lipoproteins, HDL

The plasma cholesterol, TG,LDG,HDL of 101 Korean hypertensive patients were measured to compare with plasma cholesterol, TG,LDL,HDL level of healthy people(control group). The plasma cholesterol level in hypertensive patients was 189.6+/-39.5mg% and was 188.7+/-33.7mg% in healthy people(P>0.5). The plasma TG level in hypertensive patients was 200.5+/-154.2mg% and was 116.1+/-32.4mg% in healthy people(P<0.05). The plasma HDL level in hypertensive patients was 44.6+/-15.5mg% and was 45.1+/-9.8mg% in healthy people(P>0.05). The plasma LDL level in hypertensive patients was 119.0+/-68.6mg% and was 98.1+/-53.4mg% in healthy people(P>0.05). The serum level of the total cholesterol, HDL and LDL cholesterol in the hypertensive patients group were not significantly different from the control group, but the serum level of the TG was significantly increased in the patients group. We thought that this difference of plasma TG level is due to exogenous TG in hypertensive patient group but further evalution in properties of TG is required.
Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Humans ; Plasma

OBJECTIVE: To study the serum lipid profile in children with different subtypes of juvenile idiopathic arthritis (JIA) during active and remission stages, as well as the long-term risk of atherosclerosis in children with JIA. METHODS: A total of 128 children newly diagnosed with active JIA were divided into oligoarticular JIA group with 48 children, polyarticular JIA group with 38 children, systemic JIA group with 22 children, and enthesitis-related JIA group with 20 children. According to the presence or absence of rheumatoid factor (RF), the polyarticular JIA group was further divided into RF-positive polyarticular JIA group with 15 children and RF-negative polyarticular JIA group with 23 children. A total of 45 children who underwent physical examination were randomly selected as healthy control group. The serum levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured and compared between groups. Blood lipid parameters were reexamined for 87 children in the remission stage after treatment and were compared with those in the active stage. RESULTS: Compared with the healthy control group, the systemic JIA group and the RF-positive polyarticular JIA group had a significant reduction in HDL-C and a significant increase in TG (P<0.05) in the active stage, while there were no significant differences in TC and LDL-C (P>0.05). There were no significant differences in blood lipid parameters between the other subtype JIA groups and the healthy control group (P>0.05). The RF-positive polyarticular JIA group had a significant increase in plasma HDL-C from the active stage to the remission stage (P<0.05), while the other subtype JIA groups had no significant changes in blood lipid parameters (P>0.05). CONCLUSIONS Dyslipidemia may be observed in the active stage of children with systemic and RF-positive polyarticular JIA, with improvement in the remission stage of children with RF-positive polyarticular JIA. Further studies are needed to observe the long-term risk of atherosclerosis.
Arthritis, Juvenile ; Child ; Cholesterol, HDL ; Humans ; Triglycerides

10 Patients with primary hypercholesterolemia were treated for 12 weeks with lovastation(20mg t.i.d). Lovastatin reduced mean total and low density lipoprotein cholesterol by 43% and 57% respectively(p<0.001). High density lipoprotein cholesterol and triglyceride levels were unchanged by the drug. Adverse effects attributable to lovastatin were not observed. Thus lovastatin is considered as an effective lipid lowering agent for the treatment of primary moderate hypercholesterolemia.
Cholesterol, HDL ; Cholesterol, LDL ; Humans ; Hypercholesterolemia* ; Lovastatin* ; Triglycerides

Cholesterol ; Cholesterol, HDL ; Coronary Angiography ; Coronary Artery Disease ; Humans

BACKGROUND AND OBJECTIVES: The clinical significance of statin-induced high-density lipoprotein cholesterol (HDL-C) changes is not well known. We investigated whether rosuvastatin-induced HDL-C changes can influence the anti-oxidative action of high-density lipoprotein particle. SUBJECTS AND METHODS: A total of 240 patients with stable ischemic heart disease were studied. Anti-oxidative property was assessed by paraoxonase 1 (PON1) activity. We compared the lipid profile and PON1 activity at baseline and at 8 weeks after rosuvastatin 10 mg treatment. RESULTS: Rosuvastatin treatment increased the mean HDL-C concentration by 1.9±9.2 mg/dL (6.4±21.4%). HDL-C increased in 138 patients (57.5%), but decreased in 102 patients (42.5%) after statin treatment. PON1 activity increased to 19.1% in all patients. In both, the patients with increased HDL-C and with decreased HDL-C, PON1 activity significantly increased after rosuvastatin treatment (+19.3% in increased HDL-C responder; p=0.018, +18.8% in decreased HDL-C responder; p=0.045 by paired t-test). Baseline PON1 activity modestly correlated with HDL-C levels (r=0.248, p=0.009); however, the PON1 activity evaluated during the course of the treatment did not correlate with HDL-C levels (r=0.153, p=0.075). CONCLUSION: Rosuvastatin treatment improved the anti-oxidative properties as assessed by PON1 activity, regardless of on-treatment HDL-C levels, in patients with stable ischemic heart disease.
Aryldialkylphosphatase ; Cholesterol ; Cholesterol, HDL* ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Lipoproteins ; Lipoproteins, HDL ; Myocardial Ischemia* ; Rosuvastatin Calcium*

Cardiovascular Diseases ; Cholesterol, HDL ; Cholesterol, LDL ; Humans ; Lipoproteins, HDL ; Risk Factors

To evaluate the efficacy and safety of lovastatin, new hypolipidemic agent of HMG-CoA reductase inhibitor, we administered lovastatin 40mg to 80mg once daily for 12 weeks in 20 patients(7 males, 13 females) with primary hypercholesterolemia, and observed the sequential chamges of the lipid profile every 4 weeks. The results are as follows ; 1) The seurm total cholesterol was reduced significantly by 31% from 321+/-36mg% to 210+/-26mg%(p<0.05). 2) The serum triglycerides was significantly reduced from 321+/-168mg% to 228+/-74mg% by 29%(p<0.05). 3) The low density lipoprotein cholesterol was reduced significantly from 177+/-36mg% to 120+/-22mg% by 32%(p<0.05). 4) The total lipid, high density lipoprotein cholesterol and very low density lipoprotein cholesterol were also reduced significantly. 5) The ratio between total cholesterol and high density lipoprotein cholesterol, low density lipoprotein cholesterol and high density lipoprotein cholesterol did not change after lovastatin therapy. 6) There was no adverse reaction due to lovastatin therapy during 12 weeks of therapy. These results suggested that lovastatin is a effective and safe now hypolipidemic agent and is a convenient HMG-CoA reductase inhibitor for clinical use.
Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Cholesterol, VLDL ; Humans ; Hypercholesterolemia* ; Lovastatin* ; Male ; Oxidoreductases ; Triglycerides

Our study surveded 418 obese first grade elementary school children(279 male and 139 female), in seoul, and measured levels of serum total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride were measured in addition to the measurement of body weight and height. The following results were obtained. 1) Obesity index was catergorized into mild, moderate, and severe, and the percentage of mild was 6.8%, moderate 48%, severe 45.7% respectively in surveyed children. 2) The average level of total cholesterol was 1.66.60 27.63mg/dl, HDL cholesterol 50.22+/-0.68mg/dl, LDL cholesterol 82.23+/-1.26mg/dl. 3) Atherogenic index was calculated, and obtained value was 2.45+/-0.48. It showed higher statstical significance in boys than in girls(p<0.05). 4) There was no significant difference in average level of total cholesterol, LDL cholesterol, and triglyceride in accordance of the severity of obesity. 5) Statistical significance was found in different average ievels of HDL cholesterol and atherogenic index according to obesity index (p<0.05). 6) There was a statistical significance in the average values of Kaup index and Rohrer index in accordance with obesity index (p<0.000). 7) There was no correlation between abnormal levels of total cholesterol, HDL cholesterol, and LDL cholesterol and the severity of obesity. 8) Abnormal levels of triglyceride, atherogenic index, Rohrer index and Kaup index had a statistical significance since their levels. 9) There was a correlation between atherogenic index and body measurement. Total cholesterol level showed correlation with obesity index, and HDL cholesterol with Kaup index and arm circum ference.
Arm ; Body Weight ; Child ; Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Humans ; Male ; Obesity ; Seoul* ; Triglycerides

BACKGROUND AND OBJECTIVES: Significant seasonal variations have been found by several authors in serum lipids. The aim of this study was to determine whethere there were seasonal variations in serum lipid concentrations in Korean healthy population. METHODS AND MATERIALS: The subjects consisted of 20,819 men and 10,248 women screened between January in 1997 and December in 1997. We performed spectral analyses to confirm whether there is seasonal variation in serum lipid levels. RESULTS: The monthly serum total cholesterol, HDL cholesterol and LDL cholesterol levels were significantly higher in the period from September to December with the peak in October (p<0.001, except, HDL cholesterol p<0.02), and by the seasonal analysis, these lipid levels in autumn were significantly higher than those in spring and summer (p<0.001). Those patterns of monthly and seasonal variations were similar in both men and women. Howevere triglycerides levels were slightly different by the sex. In men, significantly increased triglycerides levels were found in the period from August to December with the peak in September and those in autumn were the highest (p<0.025). In women, serum triglycerides levels were significantly higher in the period from July to February with the peak in December (p<0.04). Serum triglyceride levels in winter were higher compared with in spring and summer (p<0.001). Additionally, we analysed the seasonal variations of serum lipid levels according to the body mass index (BMI) and the age groups. In these analysis, there were also similar patterns of seasonal variations in serum lipid levels (p<0.001). CONCLUSIONS: Above results show that there were prominent seasonal variations of serum lipid levels with higher in autumn and winter compared with those in spring and summer.
Body Mass Index ; Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Female ; Humans ; Male ; Seasons* ; Triglycerides